ArticleResearch square2026
Sparse-Observation Multi-Horizon Glaucoma Progression Forecasting with Biologically Constrained Temporal Consistency: A Glaucoma Case Study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glaucoma progression forecasting from sparse longitudinal data remains unsolved, as existing models require dense multi-year inputs and lack the biological constraints. We introduce a sparse-observation framework that predicts multi-horizon outcomes from only two visits, incorporating a novel TCMH (Temporally Consistent Multi-Horizon) loss that enforces monotonic risk ordering to reflect irreversible disease biology. Applied to glaucoma progression, we integrate circumpapillary retinal nerve fiber layer (cpRNFL) images, visual field total deviation (VFTD) maps, and clinical covariates through ConvNeXt architecture trained with TCMH loss. In 3,593 patients (13,087 sequences), our model achieved AUROC 0.968 and accuracy 0.947 for two-, three-, and four-year progression forecasting, with 10.2% better calibration than baseline and 0.0163 maximum demographic disparity. At 90% coverage, classification error remained 2.5%, enabling automated risk stratification with expert review for only uncertain cases. The model exceeded three independent specialist graders on specificity (0.98 vs. 0.57-0.73) on 108 held-out eyes. These results establish sparse-observation temporally consistent forecasting as a generalizable paradigm for calibrated long-horizon risk prediction in irreversible progressive diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.